Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways
KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
3,013 announcements with these filters
KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.
Q2 FY27 standalone revenue ₹554.2 Cr (+65.0% YoY), PAT ₹28.5 Cr (+173.9%). H1 revenue ₹983.4 Cr (+23.4%), PAT ₹45.9 Cr (+34.8%). Growth from Perundurai restart and value-added products; solar expansion underway.
Q2 FY27 revenue ₹575.7 Cr (+248% YoY) on handovers; PAT ₹51.0 Cr (+85%); record Q2 booking value ₹834 Cr; senior-living focus, net cash balance sheet.
H1 FY27 consolidated revenue ₹241.3 Cr (+23% YoY), EBITDA ₹47.5 Cr, PAT ₹22.4 Cr (9.2% margin). Standalone revenue ₹215.5 Cr (+12%), PAT down 7%.
H1 FY27 consolidated revenue ₹8,291 Cr (+26%) and PAT attributable ₹2,645 Cr (+27%); Q2 PAT ₹1,549 Cr (+52%). Hydro pipeline and ₹15,000 Cr FY27 capex plan.
Q2 FY27 consolidated revenue ₹1,755.6 Mn (+40.5% YoY), PAT ₹305.7 Mn (+35.5%). H1 FY27 revenue ₹3,422.2 Mn (+50.0%), PAT ₹602.9 Mn (+117.0%). Order book ₹31,780 Mn.
Q2 FY27 consolidated revenue INR 79,682 Mn (+16.6% YoY), EBITDA INR 8,554 Mn (-16.2%), margin 10.7% (-421 bps). India-led growth with margin compression.
Krishival Foods delivered robust growth across nuts and ice cream segments despite FMCG headwinds, with aggressive capacity expansion and network scaling driving performance.
Q2 FY27 revenue Rs 609 Mn (+22% YoY), EBITDA Rs 145 Mn (23.8% margin), PAT Rs 85 Mn (+23% YoY). H1 PAT Rs 131 Mn (+19%). Management highlights capacity expansion and US presence.
Balkrishna Industries reported strong Q2 volume growth but margins faced severe headwinds from raw material inflation and freight costs.
H1 FY27 revenue ₹158 Cr (+42% YoY), EBITDA ₹15 Cr (+37%, 10% margin), PAT ₹4 Cr (-16%). Debt reduced; EPC and solar pump growth push continues.
Q2 FY27 revenue Rs2,070Mn (+19.6% YoY), PAT Rs334Mn (+26.3%), EBITDA margin 24.5%. Enterprise Solutions drives growth; certificate incident to hit H2 revenue.
H1 FY27 standalone revenue ₹99.36 Cr (+38.2% YoY), PAT ₹20.11 Cr (+54.9%), but EBITDA margin fell 225 bps to 26.35%. Order book ₹865 Cr; GMR Australia acquired.
Q2FY27 revenue INR 5,943 Mn (+42% YoY), EBITDA INR 1,155 Mn (19.4% margin), PAT INR 777 Mn (+48% YoY). H1 PAT up 108%. Order book INR 19,936 Mn.
Q2 FY27 consolidated revenue ₹275.7 Cr (+14.6%), EBITDA ₹54.1 Cr (19.4% margin), PAT after MI ₹28.4 Cr (+4.3%). Capacity expansions on track for end-FY27.
Q2 FY27 consolidated revenue INR 717 Mn (+2.8% YoY), EBITDA INR 431 Mn (60.1% margin), PAT INR 153 Mn (-7.7% YoY). Growth thesis rests on telecom capex cycle from Vodafone Idea and BSNL.
Revenue rose 32.5% to ₹2,845 Cr and PAT more than doubled to ₹232 Cr. Management is confident on growth but hedges on the 25% long-term margin, which has no timeframe. Rupee weakness is the main product-margin headwind, and management says it is solved structurally over time.
Q2 FY27 record consolidated PAT of ₹120 Cr (+7% YoY) on revenue of ₹15,836 Cr (-27% YoY); EBITDA margin 1.14%; scrap-led mix shift.
Q2FY27 revenue Rs174 Cr (+18% YoY), PAT Rs4.2 Cr (flat), EBITDA margin 7.9% (vs 11.0%) as polymer costs outran pricing.
Q2FY27 revenue ₹1,817cr (+36%), EBITDA ₹196cr (+68%), PAT ₹120cr (+80%). H1 PAT ₹286cr already exceeds FY26 full-year PAT of ₹267cr.
Headline consolidated revenue rose 47.5% in Q2, but net revenue excluding alloy pass-through grew 29.5%; PAT ₹102 Cr, +27.3%. Management is upbeat and deflects margin dilution from aluminium prices to absolute EBITDA growth.
H1 FY27 consolidated revenue ₹95.21 Cr (+27.5%), EBITDA ₹16.44 Cr (17.27% margin), PAT ₹12.03 Cr (+32.5%). Recurring mix 87%; FY27 outlook raised to ₹202 Cr.
Q2FY27 consolidated revenue rose 25.4% YoY to ₹854 Cr. EBITDA reached ₹100 Cr at an 11.7% margin, and PAT was ₹42 Cr versus ₹15 Cr.
Q2 FY27 consolidated revenue ₹85.66 Cr (+28.5%), EBITDA ₹14.77 Cr (+53%), EBITDA margin 17.24%, PAT ₹6.82 Cr (+17.6%). Dual-engine strategy: premium nuts plus ice cream.
Q2 FY27: revenue ₹3,006 Cr (+28%), EBITDA ₹263 Cr (+65%, 8.7% margin), PAT ₹101 Cr (+207%). Growth is real, but the festive quarter is unfinished and H1 operating cash flow is negative.
Q2 FY27 consolidated revenue fell 9% to INR17,018Mn, EBITDA margin compressed to 14%, and PAT fell 70%. Domestic and Biologicals grew; agchem exports declined 18%.
Consolidated Q2 PAT rose to ₹80 Cr, but standalone PAT halved and H1 consolidated PAT fell to ₹35 Cr. H2 needs ~₹4,200 Cr revenue, a steep ramp from H1's ₹1,790 Cr standalone.
Q2 revenue grew only 3.4% YoY, while EBITDA rose 24% on pricing and cost cuts, not volume. Management kept 10% CAGR revenue guidance despite ~7% H1 growth. The 15% EBITDA margin target is framed as an aspiration.
Revenue ₹1,180 Cr, up 21% YoY, flattered by low base and GST tailwinds; underlying growth 12–13%. EBITDA margin held near 34% despite ~120 bps gross margin dilution. PAT boosted by a ₹42 Cr one-off.
Q2 FY27 pre-sales ₹2,092 Cr (~14x YoY); H1 FY27 pre-sales ₹3,184 Cr, collections ₹1,051 Cr. Reported P&L is small (FY26 revenue ₹199.4 Cr, PBT ₹23.3 Cr); ₹4,800–5,700 Cr embedded PBT to be recognised FY28–FY31.